January 22, 2020

Risankizumab outperforms secukinumab in phase 3 study Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.   ADVERTISEMENT

Quality of life tied to disease severity for kids with PsO Pediatric patients with psoriasis who experience a significant improvement in disease severity after treatment may experience the greatest positive impact to quality of life, according to a recent study. ADVERTISEMENT